Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mediator

- PMLiVE

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

Approximately 16,000 people in the US are diagnosed with myelodysplastic syndromes every year

- PMLiVE

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

The investigational treatment regimen met its primary endpoint of overall survival

- PMLiVE

London High Court rules in favour of NHS in Servier drug dispute

The judgement is a key milestone in the 11-year case between the French pharmaceutical company and the secretary of state for health and social care and the wider NHS

- PMLiVE

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The NHS alleged that the French pharma company tried to block sales of generics versions of its drug Coversyl

- PMLiVE

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Oncodesign received the first milestone payment in February 2020 as part of the collaboration

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death

- PMLiVE

Trial of Amgen, Servier’s heart failure drug clears interim check

Drug could become a $2bn product if approved

- PMLiVE

Servier and Oncodesign reach first milestone in Parkinson’s partnership

Oncodesign receives first success payment of €1m

- PMLiVE

Servier faces manslaughter trial over weight loss drug deaths

Drug shown to damage heart and thought to cause death

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

- PMLiVE

Servier begins construction of new R&D hub in Paris

Centre to open by 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links